| 25.09 0.97 (4.02%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 29.81 | 1-year : | 34.82 |
| Resists | First : | 25.53 | Second : | 29.81 |
| Pivot price | 23.35 |
|||
| Supports | First : | 22.8 | Second : | 21.12 |
| MAs | MA(5) : | 24.52 |
MA(20) : | 23.13 |
| MA(100) : | 26.55  |
MA(250) : | 20.58 |
|
| MACD | MACD : | 0 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 83.9 |
| RSI | RSI(14): 58 |
|||
| 52-week | High : | 31.77 | Low : | 12.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ARQT ] has closed below upper band by 12.8%. Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.48 - 25.64 | 25.64 - 25.78 |
| Low: | 23.87 - 24.04 | 24.04 - 24.21 |
| Close: | 24.81 - 25.08 | 25.08 - 25.33 |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Tue, 14 Apr 2026
ARQT: ZORYVE’s growth accelerates with expanded access, new indications, and robust pipeline investments - TradingView — Track All Markets
Sat, 11 Apr 2026
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Tue, 07 Apr 2026
Why Arcutis Biotherapeutics (ARQT) Is Up 10.9% After Positive Infant Atopic Dermatitis Trial Data And What's Next - simplywall.st
Fri, 03 Apr 2026
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - Stock Titan
Thu, 26 Mar 2026
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Sun, 22 Mar 2026
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 124 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 108.6 (%) |
| Shares Short | 15,750 (K) |
| Shares Short P.Month | 16,380 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.53 |
| Profit Margin | -4.3 % |
| Operating Margin | 14.1 % |
| Return on Assets (ttm) | -2 % |
| Return on Equity (ttm) | -9.4 % |
| Qtrly Rev. Growth | 81.5 % |
| Gross Profit (p.s.) | 2.73 |
| Sales Per Share | 3.03 |
| EBITDA (p.s.) | -0.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -193.01 |
| PEG Ratio | 0 |
| Price to Book value | 16.29 |
| Price to Sales | 8.27 |
| Price to Cash Flow | -553.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|